Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Amylyx Pharmaceuticals, Inc. - Common Stock (NQ: AMLX )

3.730 +0.240 (+6.88%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 11, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Amylyx Pharmaceuticals, Inc. - Common Stock

< Previous 1 2
...
7 8 9 10 11 12 13 14 Next >
Amylyx Pharmaceuticals to Present Clinical Trial Design of ORION, a Phase 3 Global Study of AMX0035 in Progressive Supranuclear Palsy (PSP), at the Neuro2023 PSP and CBD International Research Symposium
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
3 Under-the-Radar Biotech Stocks to Buy in 2023
These three lesser-known biotech companies are profitable and growing revenue. 
Via The Motley Fool
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Amylyx Pharmaceuticals Receives Negative CHMP Opinion on its Marketing Authorisation Application for AMX0035 for the Treatment of ALS in the European Union Following Re-Examination Process
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Expert Ratings for Amylyx Pharma
Via Benzinga
2 Incredible Growth Stocks Near 52-Week Lows to Buy Now
These two high-tech bio companies may be too cheap to ignore right now. 
Via The Motley Fool
Amylyx Pharmaceuticals Announces Publication of Survival Analysis Comparing CENTAUR to Historical Clinical Trial Control
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Amylyx Pharmaceuticals Provides Update on Accès Compassionnel for AMX0035 in France
From Amylyx Pharmaceuticals
Via Business Wire
A Preview Of Amylyx Pharma's Earnings
Via Benzinga
Why Shares of Amylyx Pharmaceuticals Were Up Monday
The company got a bump from an analyst's upgrade. 
Via The Motley Fool
4 Analysts Have This to Say About Amylyx Pharma
Via Benzinga
RELYVRIO® and AMX0114 Data to be Presented at 22nd Annual Northeast ALS Consortium (NEALS) Meeting
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Amylyx Pharmaceuticals to Participate in Upcoming Investor Conferences
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
3 Up-and-Coming Biotech Stocks to Put on Your Must-Buy List
Here are some intriguing up-and-coming biotech stocks that may reward risk-tolerant investors with a long-term outlook. 
Via InvestorPlace
7 Analysts Have This to Say About Amylyx Pharma
Via Benzinga
What 7 Analyst Ratings Have To Say About Amylyx Pharma
Via Benzinga
Amylyx Pharmaceuticals Reports Second Quarter 2023 Financial Results
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Amylyx Pharmaceuticals to Report Second Quarter 2023 Financial Results on August 10, 2023
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
3 Biotech Stocks to Buy Before Drug Trials End
Drug trials are a chance for high risk, high reward investing. These stocks doing neurodegenerative trials could be set for big gains. 
Via InvestorPlace
Amylyx Stock Has A Good Entry Point, Says Bullish Goldman Sachs
Shares of Amylyx Pharmaceuticals Inc (NASDAQ: AMLX) jumped in early trading on Monday, after remaining broadly flat last week. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 24, 2023
Via Benzinga
Amylyx Pharmaceuticals to Host Virtual Webcast on AMX0035 Progressive Supranuclear Palsy (PSP) Program
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
EMA's Advisory Panel Gives Thumbs Down To Amylyx Pharma's Amyotrophic Lateral Sclerosis Treatment
The European Medicines Agency's Committee for Medicinal Products for Human Use has adopted a negative opinion regarding Amylyx Pharmaceuticals Inc's (NASDAQ: AMLX) conditional marketing authorization... 
Via Benzinga
Amylyx Pharmaceuticals Receives CHMP Negative Opinion on its Conditional Marketing Authorisation Application for AMX0035 for the Treatment of ALS in the European Union
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Amylyx Pharmaceuticals Completes Negotiation Process and Signs Letter of Intent with the pCPA for ALBRIOZA™ for the Treatment of ALS
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Better Growth Stock: Amylyx Pharmaceuticals or Viking Therapeutics?
Which of these red-hot biotech stocks is the better buy right now? 
Via The Motley Fool
Amylyx Pharmaceuticals to Present at the Goldman Sachs 44th Annual Global Healthcare Conference
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
How Biohaven Is Coming 'Out Of Stealth Mode' — And Bullishly Extending A 4-Day Run
Shares surged into and out of the company's R&D Day, which included a surprise. 
Via Investor's Business Daily
Amylyx Pharmaceuticals Provides Update on Ongoing Regulatory Review of AMX0035 for the Treatment of ALS in the European Union
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Amylyx Pharmaceuticals Turns Profitable On Successful Drug Launch
Amylyx Pharmaceuticals is the rare young biotech that's profitable. The company earned $0.02 a share in Q1, and analysts expect profitability to grow. 
Via MarketBeat
< Previous 1 2
...
7 8 9 10 11 12 13 14 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.